| Budget Amount *help |
¥18,980,000 (Direct Cost: ¥14,600,000、Indirect Cost: ¥4,380,000)
Fiscal Year 2018: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2017: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2016: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
|
|---|
| Outline of Final Research Achievements |
If we could synthesize these drug candidates at the disease tissue directly in vivo, potential benefits are that side effects to other organs may be lessened and the therapeutic window of drug activity can be prolonged before decomposition. We referred to this new clinical approach as "Therapeutic In Vivo Synthetic Chemistry".
One promising strategy is to use transition metal catalyzed reaction in vivo. We developed new metal-catalyzed (or mediated) transformations in biologically relevant media. To perform this reaction selectively in vivo at targeted organs, we designed a strategy that conjugates transition metal catalysts to glycoclusters, which quickly and selectively accumulate to target organs. Following injection of these metal conjugated glycoclusters into mice, we then injected the reagents to label or synthesizing the molecules at the targeted organs in mice. Our strategy led to the first example of organ selective metal catalyzed reactions.
|
